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Abstract   
 
The human skin blanching (vasoconstriction) assay for the assessment of topical 
corticosteroids uses the skin pallor induced at the site of application as an indicator of the 
potency of the drug or efficacy of the delivery vehicle. Usually several volunteers and several 
visual observers are used in the bioassay to counteract the subjectiveness of the methodology. 
Given the inherent biological variability of the population, the minimum number of 
volunteers and observers required to give valid results in this assay has not been firmly 
established. This investigation consisted of three identical trials performed at 8 week 
intervals, utilising the same 18 volunteers and the same three observers in an attempt to 
address the question of intra- and inter-volunteer and observer reproducibility of the results 
from three replicate experiments. The results indicate that for any assay utilising this 
methodology, the number of application sites for a topical corticosteroid formulation should 
be at least 48, the number of volunteers (of either sex) should be not less than nine and the 
number of observers not less than two.   
 
1. Introduction  
 
It is well established in the natural, medical and pharmaceutical sciences that, due to inherent 
bio- logical variability, repeated measurements of the same response do not necessarily 
produce the same results (Larsen et al., 1984). The human skin blanching assay makes use of 
the response of whitening in human skin produced on topical application of corticosteroids. 
The intensity of blanching is measured since this is directly related It is well established in 
the natural, medical and pharmaceutical sciences that, due to inherent bio-logical variability, 
repeated measurements of the same response do not necessarily produce the same results 
(Larsen et al., 1984). The human skin blanching assay makes use of the response of 
whitening in human skin produced on topical application of corticosteroids. The intensity of 
blanching is measured since this is directly related to the clinical efficacy of the formulation 
(Cornell and Stoughton, 1985). The application of corticosteroids to human skin does not 
induce pallor in all individuals (Harding et al., 1985). It is known that the thickness of the 
stratum corneum from the same region of the body differs between individuals, with the 
number of cell layers ranging from 12 to 30 (Kligman, 1984).  
 
Since the human skin blanching assay measures the rate and extent to which a topical 
corticosteroid diffuses from the formulation and passes through the stratum corneum to the 
vasculature, these differences in the physiological properties of human skin must produce 
different results in different individuals after topical application of the same corticosteroid. 
Given this known variability in the permeability of the stratum corneum, it would clearly be 
invalid to perform an assay of this type on a single individual. The question then arises of 
how many individuals are necessary to produce meaningful results. A large number of 
blanching studies have been reported in the literature and the numbers of subjects utilised in 
each study varies from five (Montenegro et al., 1996) to 50 (Stewart et al., 1973)    
 
A compounding problem is the number of sites utilised on anyone individual. Some 
published conclusions are derived from single applications on a number of individuals, some 
from a number of applications on a single individual and some from a number of applications 
on a number of individuals. Other volunteer variables are the ability to produce strong or 
weak blanching, the sex of the volunteer and the fact that the left and right arm may react    
differently. All three of these variables were addressed in this study.   
 
Whilst the methodology of the human skin blanching assay is generally well accepted by the 
scientific community at large, the subjective nature of the visual assessment of the intensity 
of pallor has been criticised (Stoughton, 1987; Shah et al., 1989). Many reports have 
appeared in the literature concerning objective assessment techniques as alternative methods 
of assessing skin blanching. Reflectance (Ryatt et al., 1982), thermographic (Aiache et al., 
1980) and laser Doppler velocimetry (Stevenson et al., 1987) techniques have been 
developed in an attempt to record the degree of skin blanching at each application site in a 
more quantitative manner. The chromameter, which measures skin colour by reflectance, has 
been in use for about 5 years and it has been reported (Clarys et al., 1995; Pershing, 1995; 
Montenegro et al., 1996) that objective measurements of skin colour can be  made using this 
instrument. 
 
Subjective assessments should be performed with care; training of observers is essential. In 
most reports, observations of pallor appear to be made by the researchers themselves, 
although there have been reports in which some observations were made by the volunteers 
(Gruvstad and Bengteson, 1980). Since this method is subjective, it seems reasonable to 
suggest that there must be some kind of internal monitoring of the ability of an observer to 
provide consistent evaluations of blanching. The most commonly reported method for 
providing this check is the inclusion of more than one observer in anyone trial, but the 
number of observers required to ensure accuracy of readings seems to be undecided. The 
number of observers employed in reported studies ranges from one (Stoughton and Cornell, 
1987) to five (Clanachan et al., 1980). The results reported here are an attempt to assess the 
number of observers, volunteers and application sites required for the human skin blanching  
assay to produce meaningful results. 
 
2. Materials and methods   
 
This investigation consisted of three identical trials performed at 8 week intervals, utilising 
the same 18 volunteers, the same three observers and two commercially available 
betamethasone 17- valerate (0.12%) creams (Betnovate cream, Glaxo, South Africa and 
Celestoderm- V cream, Schering- Plough, South Africa). Each preparation was applied to six 
sites on each arm of the volunteers: Both arms were left unoccluded and the formulations 
were left on the arms for 6 h. The degree of blanching was estimated at 7, 8, 9, 10, 12, 14, 16, 
18, 28 and 32 h after application of the corticosteroid formulations. The complete  
experimental protocol has previously been reported (Haigh et al., 1997)   
 
 
Blanching profiles of both formulations for each trial were produced as follows:   
 
1. For each volunteer assessed by three observers.   
 
2. For each observer incorporating 18 volunteers.   
 
3. For the nine male and the nine female volunteers assessed by three observers.   
 
4. For strong and weak arms of 18 volunteers assessed by three observers.   
 
3. Results and discussion   
 
Fig. 1 depicts the blanching curves obtained for the group of nine males and nine females and 
Fig. 2 shows the blanching curves for strong and weak arms. Table 1 lists the area under the 
blanching curve (AUBC) values for all 18 volunteers for all three trials, Table 2 for males 
and females and for strong and weak arms.   
 
It is clear that there are considerable inter- and intra-individual variations in the intensity of 
topical corticosteroid induced skin blanching. Intraindividual precision is best for volunteer 
5, Celestoderm-V formulation (AUBC mean value of 849.0 with a S.D. 14.4) and worst for 
volunteer 13, Betnovate formulation (AUBC mean value of 426.7 with a S.D.141.5). It might 
be expected that the same person would display the same degree of blanching on application 
of the same amount of corticosteroid on different occasions. It is evident from the above 
results that this is the case only with some individuals, others show large differences on 
replicate applications.   
 
Why individuals should react differently to the same corticosteroid on replicate application is 
uncertain. A medical history was obtained from each volunteer before the commencement of 
the study. Three of the female volunteers were taking oral contraceptives during all three 
trials but the shapes of the blanching curves constructed for them were normal. Female 
volunteers were required to provide details of their menstrual cycles. Only one irregular cycle 
was reported, that of volunteer 17 who displayed the lowest degree of blanching. It was not 
possible to correlate the results obtained with individual medical histories.   
 
 
 
 
 
 
 
Inter-individual variations are remarkably constant. Calculated as a percentage of the lowest 
AUBC to the highest AUBC for each preparation in each trial, inter-individual variability 
ranges from 20-30%. Biological variability is the obvious explanation for these differences 
which are commonly observed in trials of this nature.   
 
Since one of the reasons for performing this assay is to differentiate between formulations on 
the basis of the intensity of blanching, and given the large degree of variability of blanching 
between individuals, it is necessary to determine whether this individual variability will 
effect the final result. As can be seen from Table 1, of the 54 AUBC values reported, 47 
indicate that Celestoderm- V produces a higher degree of blanching than Betnovate. All of 
the seven cases of reversal show marginally greater blanching in favour of Betnovate but 
only occur in certain trials for any one individual, the other trials showing the expected rank 
order.   
 
The number of volunteers reported to be required in a study of this type has varied 
considerably. Clearly it is important to have enough people to produce a meaningful result 
and yet to have a small enough panel to make the trial reasonably easy to perform. Coupled 
with this is the number of applications of an individual formulation. In this investigation, 
each formulation was applied to six sites per arm, i.e. 216 sites were evaluated by three 
observers at each reading time and the results pooled for final analysis. In an attempt to 
ascertain the minimum number of volunteers required to produce profiles which mirrored 
those obtained from all 18, different groups of volunteers were analyzed and blanching 
profiles produced.   
 
Random selections of nine (108 application sites), six (72 application sites) and four (48 
application sites) volunteers produced blanching profiles which were almost identical to 
those produced by all 18 volunteers in terms of the differences between the two formulations. 
The results from random selections of three volunteers showed the same results, but the 
differences between formulations were smaller. A group of six selected volunteers (which 
included the five volunteers who showed some reversals of the expected differences    
between preparations for some trials, the worst possible case) produced profiles which 
showed the expected differences between formulations, but these differences were small. 
This would indicate that nine is the smallest volunteer panel that would produce valid    
conclusions. 
 
 
 
 
 
The results were then recalculated in terms of the intensity of induced blanching as measured 
in the group of nine females and in the group of nine males. As can be seen from Fig. 1 and 
Table 2, the results obtained for trials 2 and 3 were very similar, indicating quite clearly that 
the nine males produced considerably more blanching than the nine females. Trial 1, 
however, produced different results, indicating that the degree of blanching produced was 
very similar for both males and females. It can be therefore be concluded that, on average, 
males will produce more intense blanching than females. The similarities observed in Trial 1 
may well be related to the fact that an individual often produces different intensities of 
blanching on repeated applications of the same corticosteroid. The important conclusion 
which must be drawn from this particular recalculation is that both males and females show 
exactly the same ability to discriminate between different formulations on the basis of the 
assessment of the induced skin blanching. 
 
The results were recalculated to produce blanching profiles and AUBC values for the 
different arms of all volunteers. Arms were divided into strong (writing) and weak arms as 
opposed to right or left arms. Since only two of the 18 volunteers were left-handed, 
comparisons are essentially between right and left arms. It can be seen from Fig. 2 and Table 
2 that the arms of individuals are essentially identical in terms of the assessed induced 
blanching and the ability to discriminate between products. In this trial, both arms were 
treated similarly, i.e. they were both unoccluded. In many trials of this type, one arm is 
occluded and one left unoccluded. Since the arms are equivalent, it is obvious that it is   
unimportant which arm is occluded if the trial demands such a protocol. 
 
 
Figs. 3-5 represent the blanching profiles as calculated for each observer for each of the three 
trials. As can be seen from these figures and the area under the blanching curve (AUBC) 
values reported in Table 3, it is clear that individual observers assign different scores to 
corticosteroid induced blanching in human skin. Observers I and 2 showed remarkable 
consistency, however the results produced by observer 3 are substantially different from 
those recorded by observers I and 2, in the main due to lower assessments of the induced   
blanching.   
 
 
 
 
 
 
It would be unreasonable to expect three observers scoring' independently to assign the same 
scores to the blanching response elicited by a preparation in any single trial because of the 
subjective nature of the decisions required. If, however, the assay procedure and the results it 
produces are to be valid, then the same conclusions must be reached by each individual 
observer. These results show that all three observers recorded the same results in all three 
trials, i.e., the blanching produced by Celestoderm- V is always greater than that produced by 
Betnovate. Even observer 3, who scored the blanching response considerably lower than 
observers I and 2, obtained blanching profiles and AUBC values which were in agreement 
with those of observers I and 2 in terms of their ability to discriminate between    
formulations. 
 
 
 
4. Conclusions   
 
Given the large intra-individual variability of the blanching response, a number of volunteers 
must be utilised. From the results presented here, it seems that, for anyone assay utilising this 
methodology, the number of application sites for anyone topical corticosteroid formulation 
should be not less than 48 and the number of volunteers should be not less than nine. 
However, the more volunteers used and the greater the number of application sites, the more 
valid the results obtained from an in vivo assay such as the human skin blanching assay. The 
results show that the trials can be performed using male or female volunteers and the left 
and/or right arm of each volunteer without compromising the outcome. The question of how 
many observers should be utilised in anyone trial must be addressed. From the above results, 
it seems that a single observer would suffice, however, it is reasonable to suggest that a 
minimum of two observers would provide internal monitoring which would give greater 
confidence to the results obtained using this assay procedure. Utilisation of more observers 
could, however, be an advantage in that more data would be generated and this would 
produce results which would have a higher degree of relevance.   
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